WALTHAM, Mass.--(BUSINESS WIRE)--Histogenics Corporation, a late stage company focused on regenerative medicine technologies, today announced that John H. Johnson has been appointed to the company's board of directors. Mr. Johnson is currently the chairman, president and chief executive officer of Dendreon Corporation.
“We are pleased to welcome John to our board of directors,” said Garheng Kong, M.D., Ph.D., chairman of the board of directors, Histogenics. “John’s extensive industry experience in both large pharma organizations as well as venture-backed companies will be a tremendous asset for the Histogenics team.”
“I am delighted to join the Histogenics board during this exciting time in the company’s development,” said Mr. Johnson. “I believe that the company’s technologies have the potential to create novel treatments in the regenerative medicine space.”
Prior to joining Dendreon, Mr. Johnson was the chief executive officer and a member of the board of directors of Savient Pharmaceuticals, Inc., from January 2011 through January 2012. Prior to that position, Mr. Johnson served as president of Eli Lilly & Company’s Oncology Unit, following its 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer. Before joining Imclone, he served as the company group chairman of biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to assuming that role, Mr. Johnson held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp., as well as positions at Pfizer, Inc. Mr. Johnson is the former chairman of Tranzyme Pharma, Inc., and is currently a member of the board of directors for Cempra Pharmaceuticals, Inc. He also serves as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of the Biotechnology Industry Organization (BIO).
Histogenics is a late stage company focused on regenerative medicine technologies, including cell-based therapies, tissue engineering and biologics. Our lead product candidate, NeoCart®, is targeting the musculoskeletal segment of the regenerative medicine marketplace with an initial focus on treating damage to the articular cartilage of the knee using biological, cell-based therapy. For more information visit www.histogenics.com.